REGENERON PHARMACEUTICALS, INC.
REGNPharma & biotechregeneron.com
Latest available resultsSeptember 30, 2026Quarter · 10-Q filed Oct 30, 2026
Next reportJanuary 28, 2027after close · forecast 23.785 $/share
Revenue
$5.12B
▲ +36.3% vs prior year YoY
Net income
$1.95B
▲ +33.5% vs prior year YoY
EPS
18.45$
▲ +35.5% vs prior year YoY
Net margin
38.1%
▼ -0.8 pp vs prior year YoY
Revenue▲ +36.3%
Margins (% of revenue)Gross N/AOperatingNet
Net income▲ +33.5%
EPS▲ +35.5%
Financial statements
View 10-Q filed October 30, 2026 on SEC ↗| Metric | Dec 2024* | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025* | Mar 2026 | Jun 2026 | Sep 2026 | YoY |
|---|---|---|---|---|---|---|---|---|---|
| Operations | |||||||||
| Revenue | $3.79B | $3.03B | $3.68B | $3.75B | $3.88B | $3.61B | $4.29B | $5.12B | ▲ +36.3% |
| Gross profit | — | — | — | — | — | — | — | — | — |
| Operating income | $990.20M | $591.70M | $1.08B | $1.03B | $879.90M | $642.90M | $1.29B | $2.05B | ▲ +99.5% |
| Net income | $917.70M | $808.70M | $1.39B | $1.46B | $844.60M | $727.20M | $1.30B | $1.95B | ▲ +33.5% |
| R&D | $1.41B | $1.33B | $1.42B | $1.48B | $1.63B | $1.54B | $1.63B | $1.79B | ▲ +21.7% |
| EPS (diluted) | — | 7.27 $ | 12.81 $ | 13.62 $ | — | 6.75 $ | 12.23 $ | 18.45 $ | ▲ +35.5% |
| Margins (% of revenue) | |||||||||
| Gross | — | — | — | — | — | — | — | — | — |
| Operating | 26.1 % | 19.5 % | 29.4 % | 27.3 % | 22.7 % | 17.8 % | 30.1 % | 40.0 % | ▲ +12.7 pt |
| Net | 24.2 % | 26.7 % | 37.9 % | 38.9 % | 21.7 % | 20.2 % | 30.2 % | 38.1 % | ▼ -0.8 pt |
| Balance sheet | |||||||||
| Assets | $37.76B | $37.55B | $38.22B | $40.17B | $40.56B | $40.87B | $41.73B | $44.41B | ▲ +10.5% |
| Liabilities | $8.41B | $8.16B | $8.28B | $9.21B | $9.30B | $9.45B | $10.02B | $10.91B | ▲ +18.4% |
| Equity | $29.35B | $29.39B | $29.94B | $30.96B | $31.26B | $31.42B | $31.71B | $33.50B | ▲ +8.2% |
| Cash | $2.49B | $3.09B | $2.00B | $2.51B | $3.12B | $2.96B | $2.46B | $3.66B | ▲ +46.0% |
| Capital | |||||||||
| Shares outstanding | — | — | — | — | — | — | — | — | — |
| Public floatexcluding insiders | — | — | — | — | — | — | — | — | — |
* No 10-Q is filed for a fourth quarter: these amounts are the fiscal year minus the first three quarters, all filed. EPS stays blank — dilution doesn't subtract.